Tropé C - Search Results

1

Prospectively detected cancer in familial breast/ovarian cancer screening.

Dørum A, Heimdal K, Løvslett K, Kristensen G, Hansen LJ, Sandvei R, Schiefloe A, Hagen B, Himmelmann A, Jerve F, Shetelig K, Fjaerestad I, Tropé C, Møller P. Dørum A, et al. Among authors: trope c. Acta Obstet Gynecol Scand. 1999 Nov;78(10):906-11. Acta Obstet Gynecol Scand. 1999. PMID: 10577622

2

Early detection of familial ovarian cancer.

Dørum A, Kristensen GB, Abeler VM, Tropé CG, Møller P. Dørum A, et al. Among authors: trope cg. Eur J Cancer. 1996 Sep;32A(10):1645-51. doi: 10.1016/0959-8049(96)00137-2. Eur J Cancer. 1996. PMID: 8983269 Clinical Trial.

3

[Screening for ovarian cancer].

Bjørge T, Dørum A, Tropé CG. Bjørge T, et al. Among authors: trope cg. Tidsskr Nor Laegeforen. 2000 May 10;120(12):1444-8. Tidsskr Nor Laegeforen. 2000. PMID: 10851943 Review. Norwegian.

4

The problem of skipped generation and subclinical disease in familial breast-ovarian cancer.

Dørum A, Abeler VM, Heimdal K, Tropé C, Møller P. Dørum A, et al. Among authors: trope c. Acta Obstet Gynecol Scand. 1997 Feb;76(2):166-8. doi: 10.3109/00016349709050074. Acta Obstet Gynecol Scand. 1997. PMID: 9049291 Free article.

5

Endometrial cancer: the management of high-risk disease.

Kristensen G, Tropé C. Kristensen G, et al. Among authors: trope c. Curr Oncol Rep. 2004 Nov;6(6):471-5. doi: 10.1007/s11912-004-0078-2. Curr Oncol Rep. 2004. PMID: 15485617 Review.

6

The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer.

Makar AP, Baekelandt M, Tropé CG, Kristensen GB. Makar AP, et al. Among authors: trope cg. Gynecol Oncol. 1995 Feb;56(2):175-80. doi: 10.1006/gyno.1995.1027. Gynecol Oncol. 1995. PMID: 7896181

7

Evaluation of deoxyribonucleic acid ploidy and S-phase fraction as prognostic parameters in advanced epithelial ovarian carcinoma: a prospective study.

Kaern J, Tropé CG, Kristensen GB, Tveit KM, Pettersen EO. Kaern J, et al. Among authors: trope cg. Am J Obstet Gynecol. 1994 Feb;170(2):479-87. doi: 10.1016/s0002-9378(94)70215-2. Am J Obstet Gynecol. 1994. PMID: 8116701

8

Flow cytometric DNA ploidy and S-phase heterogeneity in advanced ovarian carcinoma.

Kaern J, Tropé CG, Kristensen GB, Pettersen EO. Kaern J, et al. Among authors: trope cg. Cancer. 1994 Apr 1;73(7):1870-7. doi: 10.1002/1097-0142(19940401)73:7<1870::aid-cncr2820730716>3.0.co;2-3. Cancer. 1994. PMID: 8137213

9

Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer?

Makar AP, Kristensen GB, Børmer OP, Tropé CG. Makar AP, et al. Among authors: trope cg. Gynecol Oncol. 1993 Apr;49(1):3-7. doi: 10.1006/gyno.1993.1076. Gynecol Oncol. 1993. PMID: 8482556

10

A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing.

Dørum A, Møller P, Kamsteeg EJ, Scheffer H, Burton M, Heimdal KR, Maehle LO, Hovig E, Tropé CG, van der Hout AH, van der Meulen MA, Buys CH, te Meerman GJ. Dørum A, et al. Among authors: trope cg. Eur J Cancer. 1997 Dec;33(14):2390-2. doi: 10.1016/s0959-8049(97)00328-6. Eur J Cancer. 1997. PMID: 9616287

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

452 results

Search Page